• Isabela Peña Pino, David P Darrow, and Clark C Chen.
• Department of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.
• World Neurosurg. 2024 Jan 1; 181: e833e840e833-e840.

BackgroundThe Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE) study is a phase II clinical trial testing the efficacy of a recombinant adenovirus DNX-2401 combined with the immune checkpoint inhibitor pembrolizumab. Here, we report the first patients in this study who underwent viral delivery through real-time magnetic resonance imaging (MRI) stereotaxis-guided SmartFlow convection delivery of DNX-2401.MethodsPatients who underwent real-time MRI-guided DNX-2401 delivery through the SmartFlow convection catheter were prospectively followed.ResultsPrecise catheter placement was achieved in all patients treated, and no adverse events were noted. Average radial error from target was 0.9 mm. Average procedural time was 3 hours 16 minutes and was comparable to other convection-enhanced delivery techniques. In 2 patients, delivery of DNX-2401 was visualized as >1 cm maximal diameter of T1 hypointensity infusate on MRI obtained immediately after completion of viral infusion. These patients exhibited partial response based on Response Assessment in Neuro-Oncology assessment. The remaining patient showed <1 cm maximal diameter of infusate on immediate postinfusion MRI and showed disease progression on subsequent MRI.ConclusionsOur pilot case series supports compatibility of the SmartFlow system with oncolytic adenovirus delivery and provides the basis for future validation studies.Copyright © 2023. Published by Elsevier Inc.

14 keywords...

hide…